GSK ROE 2010-2022 | GSK

Current and historical return on equity (ROE) values for GSK (GSK) over the last 10 years. Return on equity can be defined as the amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested.
GSK ROE - Return on Equity Historical Data
Date TTM Net Income Shareholder's Equity Return on Equity
2022-12-31 $18.50B $12.49B 90.74%
2022-09-30 $16.61B $10.27B 67.51%
2022-06-30 $6.07B $28.43B 20.56%
2022-03-31 $6.97B $30.37B 23.26%
2021-12-31 $6.03B $29.35B 20.36%
2021-09-30 $6.00B $29.99B 20.73%
2021-06-30 $6.00B $30.16B 21.33%
2021-03-31 $6.86B $28.97B 25.56%
2020-12-31 $7.38B $26.72B 28.37%
2020-09-30 $8.12B $26.64B 32.21%
2020-06-30 $8.42B $24.99B 34.94%
2020-03-31 $6.86B $25.74B 36.43%
2019-12-31 $5.93B $23.44B 44.00%
2019-09-30 $5.56B $22.27B 62.85%
2019-06-30 $5.49B $3.82B 122.35%
2019-03-31 $4.85B $4.39B 106.35%
2018-12-31 $4.84B $4.90B 102.56%
2018-09-30 $2.83B $4.85B 61.39%
2018-06-30 $2.57B $4.11B 51.62%
2018-03-31 $1.74B $5.00B 32.45%
2017-12-31 $1.98B $4.50B 33.75%
2017-09-30 $2.97B $6.32B 46.38%
2017-06-30 $2.45B $5.66B 39.83%
2017-03-31 $2.05B $6.93B 32.87%
2016-12-31 $1.16B $6.73B 16.93%
2016-09-30 $0.30B $5.25B 3.50%
2016-06-30 $0.07B $6.06B 0.67%
2016-03-31 $0.93B $9.37B 6.91%
2015-12-31 $12.77B $13.57B 83.05%
2015-09-30 $14.87B $14.47B 106.07%
2015-06-30 $14.68B $16.16B 114.69%
2015-03-31 $15.57B $17.30B 133.77%
2014-12-31 $4.44B $8.14B 42.76%
2014-09-30 $6.81B $9.61B 59.68%
2014-06-30 $7.73B $11.51B 66.37%
2014-03-31 $8.22B $12.30B 71.10%
2013-12-31 $8.56B $12.22B 74.82%
2013-09-30 $6.01B $10.54B 54.31%
2013-06-30 $6.25B $11.17B 55.78%
2013-03-31 $6.62B $11.84B 57.63%
2012-12-31 $7.30B $10.70B 59.34%
2012-09-30 $7.90B $11.10B 60.00%
2012-06-30 $8.28B $12.35B 60.44%
2012-03-31 $8.10B $15.04B 56.01%
2011-12-31 $8.41B $14.16B 57.33%
2011-09-30 $5.32B $13.27B 35.72%
2011-06-30 $5.21B $15.40B 33.21%
2011-03-31 $2.98B $15.83B 19.36%
2010-12-31 $2.60B $15.07B 16.32%
2010-09-30 $6.44B $16.45B 40.10%
2010-06-30 $6.60B $14.24B 41.94%
2010-03-31 $9.29B $17.84B 61.25%
2009-12-31 $8.92B $15.67B 65.52%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $75.923B $36.279B
GSK plc is a biopharma company. Its vaccine portfolio protects people from meningitis, shingles, flu, polio, measles and many more. GSK plc, formerly known as GLAXOSMITHKLINE, is based in Brentford, the United Kingdom.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $140.576B 8.70
Bio-Rad Laboratories (BIO.B) United States $13.735B 32.61
QIAGEN (QGEN) Netherlands $10.436B 19.34
Ginkgo Bioworks Holdings (DNA) United States $2.549B 0.00
Arcus Biosciences (RCUS) United States $1.194B 0.00
Biohaven (BHVN) United States $0.913B 0.00
Emergent Biosolutions (EBS) United States $0.394B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.152B 0.00
Enzo Biochem (ENZ) United States $0.106B 0.00
SQZ Biotechnologies (SQZ) United States $0.024B 0.00
Gelesis Holdings (GLS) United States $0.012B 0.00